Resources

Thank you Dr. Lisa Bodei and Prof. Michael Hofman for their instructive presentations about Theranostics and PET Imaging Diagnostics. Did you miss the webinar? Watch the recordings In addition to all questions answered at the end of this webinar, here are a few remaining ones, which Prof Hofman kindly answered: •    What´s your opinion about the cost-effectiveness of 177-Lu-PSMA compared with others options?  There is regional variation. Interestingly, in low- and lower-middle-income countries, Lu-PSMA is also widely adopted and made available to patients. In these countries where there is a fee-for-service infrastructure, Lu-PSMA is preferred by many as a cheaper option to expensive pharmaceuticals. This generally uses Lu-177-PSMA-I&T made in hospital radiopharmacies. For the USA / Europe, it is a more complex question. Lu-PSMA-PSMA-617 is approved for purchase from Novartis in a single country - Switzerland, and the cost upwards of 20,000 swiss francs per dose. We do not have yet pricing elsewhere. This will needs FDA and EMA approval first. So it is a complex landscape, but when you take into account the efficacy and toxicity of Lu-PSMA compared to other treatments, I am confident it will be a cost effective treatment. •    What about non prostate related PSMA uptake in other benign or neoplastic process? There is a range of non-prostate uptake. We have written a nice Radiographic review article on this.

As the COVID-19 crisis continues around the world, the IBA support team is working from home to keep the best remote support to all IBA users who providing cancer and other life-threatening diseases diagnosis.